Pilot Study of Accelerated rTMS Using EXOMIND Device for Improving Movement and Thinking in Mild to Moderate Parkinsons Disease in Adults Aged 50 to 90

What this Trial Is About

Parkinsons disease PD is a brain disorder causing progressive movement problems like slowness, stiffness, tremor, and difficulty walking. Many people with PD also face thinking and memory challenges. Current medications help manage movement symptoms but may lose effectiveness over time and cause side effects. Researchers are evaluating whether repetitive transcranial magnetic stimulation rTMS, a non-invasive treatment using magnetic pulses to stimulate the motor cortex, can improve movement and thinking abilities in people with mild to moderate PD. Participants in this open-label pilot study will receive 6 sessions of high-frequency rTMS using the EXOMIND173 device. Treatments are administered twice a week over about 3 weeks, targeting both sides of the primary motor cortex with 10-20 Hz stimulation at 90-110% of resting motor threshold. The study includes a screening phase up to 14 days, the treatment phase of approximately 21 days, and a follow-up phase of 90 days. No placebo or control group is involved. Participants will be assessed before treatment, at the last treatment session, and at 1-month and 3-month follow-ups. Evaluations include motor function tests MDS-UPDRS-III, gait and walking assessments, cognitive testing using the Montreal Cognitive Assessment and Creyos battery, mood questionnaires, and quality of life measures. Safety monitoring involves checking vital signs and possible adverse effects at each session and follow-up. Total study participation lasts up to 139 days.

Effects of Accelerated rTMS On Motor and Cognitive Function in Parkinson's Disease